| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MYOV | Common Stock | Purchase | $911K | +42.8K | +0.09% | $21.29 | 48.7M | Aug 16, 2021 | See Footnote | F1, F2, F3 |
| transaction | MYOV | Common Stock | Purchase | $118K | +5.38K | +0.01% | $21.94 | 48.7M | Aug 16, 2021 | See Footnote | F1, F3, F4 |
| transaction | MYOV | Common Stock | Purchase | $492K | +23.5K | +0.05% | $20.89 | 48.7M | Aug 17, 2021 | See Footnote | F5, F6, F7 |
| Id | Content |
|---|---|
| F1 | This acquisition of a total of 48,167 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the "10b5-1 Trading Plan"). |
| F2 | The transaction was executed in multiple trades ranging from $20.83 to $21.82 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. |
| F3 | Sumitovant Biopharma Ltd. ("Sumitovant") directly owns a total of 48,689,348 shares of Common Stock following the acquisition on August 16, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76 % owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. |
| F4 | The transaction was executed in multiple trades ranging from $21.84 to $22.08 per share. The price reported above reflects the weighted average purchase price. The Reporting Person herereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. |
| F5 | This acquisition of a total of 23,549 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. |
| F6 | The transaction was executed in multiple trades ranging from $20.46 to $21.15 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected. |
| F7 | Sumitovant directly owns 48,712,897 shares of Common Stock following the acquisition on August 17, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76 % owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. |